SIMULATIONS PLUS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.24 USD | -1.01% |
|
-3.19% | +7.80% |
Financials (USD)
| Sales 2024 * | 68.07M | Sales 2025 * | 76.98M | Capitalization | 964M |
|---|---|---|---|---|---|
| Net income 2024 * | 13M | Net income 2025 * | 16M | EV / Sales 2024 * | 14.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 12.5 x |
| P/E ratio 2024 * |
73.5
x | P/E ratio 2025 * |
59.6
x | Employees | 195 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on Simulations Plus, Inc.
More recommendations
More press releases
| 1 day | -1.01% | ||
| 1 week | -3.19% | ||
| 1 month | +6.37% | ||
| 3 months | +16.24% | ||
| 6 months | +23.06% | ||
| Current year | +7.80% |
1 week
47.62
49.99
1 month
46.3951.22
Current year
35.9851.22
1 year
32.6952.69
3 years
32.5867.59
5 years
24.0890.92
10 years
5.2790.92
| Managers | Title | Age | Since |
|---|---|---|---|
Shawn O'Connor
CEO | Chief Executive Officer | 65 | 18-06-25 |
| Founder | 79 | 96-07-16 | |
| Director of Finance/CFO | 61 | 20-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 96-07-16 | |
Daniel Weiner
BRD | Director/Board Member | 74 | 17-04-30 |
John Paglia
BRD | Director/Board Member | 56 | 14-12-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 48.24 | -1.01% | 90,042 |
| 24-05-30 | 48.73 | +0.39% | 63,446 |
| 24-05-29 | 48.54 | -2.43% | 51,291 |
| 24-05-28 | 49.75 | -0.16% | 88,771 |
| 24-05-24 | 49.83 | +0.32% | 54,471 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Calendar
2024-07-09
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
48.24
USD
Average target price
55.33
USD
Spread / Average Target
+14.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.80% | 974M | |
| -9.49% | 31.38B | |
| +25.35% | 8.33B | |
| +33.25% | 4.27B | |
| -35.85% | 2.47B | |
| -9.44% | 1.65B | |
| -13.39% | 1.5B | |
| -32.84% | 1.07B | |
| -37.56% | 840M | |
| -20.77% | 684M |
- Stock Market
- Equities
- SLP Stock
